This inventor holds 1 USPTO granted patent. Top assignee: S&k Therapeutics. Active years: 2026.
Company Filing History:
Years Active: 2026
Title: Innovations of Yangseon Choi in Autoimmune Disease Treatment
Introduction
Yangseon Choi is a prominent inventor based in Suwon, South Korea. He has made significant contributions to the field of therapeutic agents for autoimmune diseases. His innovative work focuses on small-molecule compounds that target endosomal toll-like receptors.
Latest Patents
Yangseon Choi holds a patent for "Small-molecule compounds for controlling endosomal toll-like receptors and therapeutic agent for autoimmune diseases using same." This patent describes antagonistic small-molecule compounds that inhibit endosomal Toll-like receptors (TLRs). Specifically, it targets TLR3, TLR7, TLR8, and TLR9 signaling pathways. The novel compound has shown promising results in a systemic lupus erythematosus animal model. It effectively prevents TNF-α secretion induced by various TLR agonists and inhibits the production of inflammatory cytokines. This suggests its potential utility in preventing or treating TLR-associated autoimmune diseases, inflammatory diseases, and viral diseases.
Career Highlights
Yangseon Choi is currently associated with S&K Therapeutics, where he continues to advance his research and development efforts. His work has garnered attention for its innovative approach to treating complex autoimmune conditions.
Collaborations
Yangseon Choi collaborates with notable colleagues, including Kevin Jaesuk Choi and Nam Hui Kim. Their combined expertise enhances the research and development initiatives at S&K Therapeutics.
Conclusion
Yangseon Choi's innovative contributions to the field of autoimmune disease treatment through his patented small-molecule compounds highlight his role as a leading inventor. His work promises to pave the way for new therapeutic options in managing autoimmune and inflammatory diseases.